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ABSTRACT A series of 27 B-cell lymphomas (designated
the CH series), induced in B1O.H-2aH4bp/Wts mice by intense
adoptive immunization with sheep erythrocytes, was found to
represent a subset of the total B-cell repertoire. This subset was
characterized by expression of a limited number of Ig heavy
chain variable regions, as evidenced by the presence of cross-
reactive idiotypes and common antigen binding specificities.
Twenty-one of the 27 CH lymphomas studied were classified
into five groups, defmed by a particular cross-reactive idiotype;
four of these groups were linked in a single network. Seven of
16 idiotypes defined by absorption analysis were present on
lymphomas bearing either K or A light chains and so were
localized to the heavy chain variable region. The surface Ig on
14 CH lymphomas was found to be specific for epitopes on
certain erythrocytes (bromelain-treated autologous erythro-
cytes, sheep, and chicken erythrocytes) or E. coUl. We propose
that the CH lymphomas represent the malignant counterparts
of a subset of idiotypically related, normal B cells in B1O.H-
2aH4bp/Wts mice. Perturbation of this idiotype network, by
hyperimmunization with an antigen for which some of the
members are specific (sheep erythrocytes), increases the risk
for neoplasia. Possible mechanisms for this are discussed.
Mice of the double congeneic strain, B1O.H-2aHW4bp/Wts
(2a4b), display a high incidence of lymphoma following
intense adoptive immunization with sheep erythrocytes
(SRBC). The tumors that arise comprise a heterogeneous
group, including the UNC series of T-cell lymphomas (1), the
CH series of B-cell lymphomas (2), and a set of lymphomas
which are not readily characterized as belonging to either the
B-cell or T-cell lineage (unpublished data). Presently avail-
able data are insufficient to define the etiology ofthis disease,
but we had found previously that xenogeneic anti-idiotype
(anti-Id) sera raised against the surface IgM of CH1 and of
CH2 each reacted with 1 other of the first 11 B-cell
lymphomas described (CH9 and CH5, respectively) (3). This
suggested that a limited subset of the total normal Id
repertoire might be expressed by the CH lymphomas [Ids are
sets of antigenic determinants (called idiotopes) associated
with Ig variable (V) regions] (4). We also had found that the
surface Ig of CH12 was specifically reactive with an epitope
present on SRBC, suggesting that adoptive immunization had
led to the expansion of a subset of B cells with neoplastic
potential (5).
In pursuit of this possible link between antigen-driven B
cell proliferation and lymphomagenesis, we now report the
results ofa study ofthe surface Ig borne by 27 different B-cell
lymphomas of 2a4b mice. The data demonstrate extensive
sharing of idiotopes, several of which can be localized to the
heavy chain variable (VH) region; 21 of the tumors can be
arranged in five cross-reactive groups, four of which are
linked in a single network. Furthermore, 14 of these
lymphomas bear surface Ig specific for epitopes present on
certain erythrocytes [SRBC, chicken erythrocytes (ChRBC),
and autologous erythrocytes treated with the proteolytic
enzyme, bromelain] or Escherichia coli. We interpet this to
imply that defective regulation of a subset of Id-related B
cells contributes to the susceptibility of 2a4b mice to antigen-
driven lymphomagenesis.
MATERIALS AND METHODS
Animals. 2a4b mice were bred and maintained in our
pathogen-free mouse colony. This strain was derived from
selected F2 progeny of B10.A x B10.129(21M) mice as
described (6). BALB/c mice were purchased from Charles
River Breeding Laboratories.
New Zealand White rabbits were used for antiserum
production.
Tumors. The CH series of B-cell lymphomas was induced
in 2a4b mice by adoptive hyperimmunization with SRBC. The
one exception to this was CH19; it arose in a 487-day-old
unmanipulated 2a4b mouse. Details concerning the inductions
of CHI-CH12 have been reported (2). The induction proto-
cols for CH15-CH39 will be presented elsewhere. These
tumors have been maintained by serial transplantation of
ascites or splenic tumor cells in syngeneic animals.
MOPC104E (provided by J. Folds) and TEPC183 (Litton
Bionetics; National Cancer Institute Contract N01-CB-
94326) plasmacytomas (7) were maintained by transplanta-
tion in pristane-primed BALB/c mice.
Characterization of Cell Surface Antigens. All of the CH
lymphomas bear surface IgM (see Table 1 and ref. 2), but
none secretes a substantial amount of IgM. One lymphoma,
CH15, expresses surface IgD as well as surface IgM;
CH19-CH39 have not been tested yet for surface IgD. I-A,
I-E, and T200/Ly-5 antigens are present on every tumor
tested, whereas Thy-1.2 is not detectable (ref. 2 and unpub-
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erythrocytes; VH, heavy chain variable region.
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Table 1. Reactivity patterns of anti-Id antisera
Anti-Id antisera raised against CH lymphomast
Tumor sIg* CH1.1 CH1.2 CH2 CH5 CH6 CH7 CH9 CH10 CH12 CH27
CH1 ,A + + - - - - + - - -
CH2 XA - - + + - - - - - -
CH4 Trace - - - - - - - - ND
CH5 A,,K - - + + - - - - - -
CH6 A,K - - - - + - - - - -
CH7 ,K - - - - - + - - - -
CH9 /.LK + - - - - - + - - -
CH10 K - - - - - - + - -
CH12 K - - - - - - - - + -
CH15 Au 8, K ND - - - - - + - - -
CH19 A, K ND - - - - - - - - -
CH21 A, K ND - - - - - - - - -
CH23 , K ND - - - - - - - + -
CH25 ,u K ND - - - - - - - + +
CH26 u, K ND - - - - - + - - -
CH27 ,u, K ND - + + - - - - - +
CH28 ,K ND - - - - - - - - +
CH29 ,K ND - - - - - - + - -
CH30 ,K ND - - - - - - - - -
CH31 ,u, K ND - - - - - - + - -
CH32 ,u, K ND - - - - - - - + +
CH33 Au K ND - - - - - - + - -
CH34 ,u, K ND - - - - - + - - -
CH35 ., K ND - - - - - - - - +
CH36 ,u, K ND - - - - - - + - -
CH38 u, K ND - - - - - - - + -
CH39 ,u, X ND - - - - - + - + -
T183 ,u Kt ND ND + + - - - - + -
ND, not done.
*Surface immunoglobulin light and heavy chains.
tThese antisera were extensively absorbed so that each reacted with >95% of the tumor cells (against which it was raised)
and with no detectable normal spleen cells. Either MOPC104E (for anti-CH1.1, anti-CH1.2, and anti-CH2) or TEPC183
(for anti-CH6, anti-CH7, anti-CH9, anti-CH10, and anti-CH27) immobilized myeloma proteins and normal spleen cells were
used in the absorptions. Anti-CH1 (1.1 and 1.2) and anti-CH2 were absorbed further with CH2 and CH1 cells, respectively.
Anti-CH5 and apti-CH12 were absorbed with CH15 cells and normal spleen cells.
*Secreted immunoglobulin light and heavy chains.
lished data). All of the CH lymphomas except CH12 and
CH27 express Fc-fragment receptors, but only CH25 ex-
presses detectable receptors for the third complement com-
ponent (CH31 and CH34 hive yet to be tested for both
receptors).
The reagents used to measure the level of the Ly-1 antigen
were: rat monoclonal anti-Ly-1 antibody (53-73.1) (8), fol-
lowed by biotin-labeled monoclonal mouse (SJL) anti-rat K
light chain antibody (MAR18.5) (9) and then avidin-
phycoerythrin conjugate (Becton Dickinson Monoclonal
Center). For negative controls, the first antibody was either
omitted or substituted with the rat monoclonal anti-Thy-1.2
antibody (30-H12) (8). An EPICS V flow cytometer (Coulter)
equipped with a logarithmic amplifier was used to measure
the fluorescence intensity of each sample.
Rosette Assays. The erythrocytes and E. coli rosette assays
have been described (5, 10). In order to determine if the
binding of antigen was due to the surface Ig, the tumor cells
were incubated with anti-Ig antisera in RPMI 1640 medium
for 60 min at 37°C (capping conditions) before the addition of
erythrocytes or E. coli. The remainder of the assay was
performed as described.
Preparation of Anti-Id Antisera. Rabbit antisera were
raised against the detergent-solubilized affinity-purified sur-
face Ig of the CH lymphomas as described (11). Each serum
(including normal rabbit serum) was absorbed extensively by
using the procedures described below. An anti-Id antiserum
was considered specific when it reacted with >95% of the
immunizing tumor cells but not with a detectable number of
normal 2a4b splenocytes (in an indirect immunofluorescence
assay) (11).
Anti-Id sera raised against the IgM X light chain-bearing
tumors (CH1 and CH2) were absorbed with immobilized
MOPC104E (,,X) myeloma protein, while those sera raised
against most of the IgM K light chain-bearing tumors (CH6,
CH7, CH9, CH10, and CH27) were absorbed with im-
mobilized TEPC183 (A,K) myeloma protein. Anti-CHi and
anti-CH2 Id sera were absorbed further with CH2 and CH1
cells, respectively. Since both CH5 and CH12 were shown to
express idiotopes shared by TEPC183, anti-Id sera raised
against these tumors were absorbed with another, nonidi-
otypically related, IgM K chain-bearing lymphoma, CH15. A
final absorption with 2a4b splenocytes was performed for all
antisera.
Each antiserum is referred to as an anti-CHXId, where X
corresponds to the number of the CH lymphoma against
which the antiserum was raised. In one case (CH1), antisera
produced in two rabbits displayed different reactivity pat-
terns (Table 1) and were labeled anti-CH1.1 Id and anti-
CH1.2 Id.
RESULTS
Expression of Ly-1. We have found (2) that 4 of the first 11
CH lymphomas (CH4, CH5, CH6, and CH12) expressed
Ly-1. Subsequently, Ly-1 was detected on CH1 by use of a
more sensitive assay. We now have examined 16 more CH
lymphomas and have found that 13 tumors express detectable
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FIG. 1. Ly-1 expression on CH lymphomas.
The indicated cells were stained either with 53-7.3
culture supernatant/biotinylated-mouse anti-rat K
light chain antibody (MAR18.5)/phycoerythrin-
240
avidin or with just biotinylated-MAR18.5/phyco-
240) erythrin-avidin (histogram indicated by arrow) and
then were analyzed by flow cytometry.
amounts of Ly-1 (+: CH19, CH21, CH23, and CH29; +/-:
CH15, CH27, CH28, CH32, CH34, CH35, and CH36;
"trace": CH31 and CH38) (see Fig. 1 for histograms of
representative lymphomas). A subset of normal B cells (12)
and several other B-cell lymphomas (13) also have been
shown to express Ly-1.
Specificity of Anti-Id Sera. We raised xenogeneic anti-Id
sera against the surface Ig borne by nine CH lymphomas and,
after exhaustive absorptions, tested each for its specificity in
an indirect immunofluorescence assay. The results of these
tests for two representative anti-Ids (anti-CH12 and anti-
CH27) are shown in Fig. 2. The anti-CH12 Id reacted strongly
with CH12 but not with CH27 or spleen cells, as compared to
the normal rabbit serum control. Similarly, the anti-CH27 Id
only bound to CH27 and not to CH12 or splenocytes.
Immunoprecipitation studies have shown that these anti-Ids
precipitate polypeptides (from the appropriate CH lymphoma
cells) with molecular weights corresponding to Ig heavy (A)
and light chains (ref. 4 and unpublished data).
Further proof of the specificity of these sera came from
antigen binding inhibition studies (see Table 4), which show
that only specific anti-Ids can inhibit the rosette formation of
erythrocytes or E. coli with the appropriate tumors. Anti-
CH10 Id, for example, abrogated the ability of CH10 to bind
E. coli, whereas anti-CH9 and anti-CH27 Id did not.
Analysis of Cross-Reactive Ids (IdX). We tested the 10
anti-Id sera against all of the CH lymphomas (Table 1). This
analysis revealed that 21 of the 27 CH lymphomas bore IdX,
as defined by 7 ofthe anti-Ids. We classified these tumors into
five groups, realizing that four of them overlapped. The five
groups and the anti-Ids that define them are (t) CH1 IdX
(CR1, CH9, CH15, CH26, CH34, and CH39; anti-CH1.1 and
anti-CH9 Ids), (ii) CH2 IdX (CH2, CH5, CH27, and
TEPC183; anti-CH2 and anti-CH5 Ids), (iii) CH10 IdX
(CH10, CH29, CH31, CH33, and CH36; anti-CH1O Id), (iv)
CH12 IdX (CH12, CH23, CH25, CH32, CH38, CH39, and
TEPC183; anti-CH12 Id), and (v) CH27 IdX (CH25, CH27,
CH28, CH32, and CH35; anti-CH27 Id). The CH1, CH2,
CH12, and CH27 IdX groups (which include 16 lymphomas)
are linked together by the following tumors: CH25, CH27,
CH32, CH39, and TEPC183 (i.e., these tumors are present in
more than one IdX group).
In order to determine the minimum number of idiotopes
expressed by the lymphomas in each IdX group, we exhaus-
tively absorbed each anti-Id with each of the tumors with
which it reacted. Each anti-Id was then retested on all of the
other tumors in the IdX group. If a tumor then failed to react
with an absorbed anti-Id, it indicated that the tumor tested
and the one used in the absorption shared at least one
idiotope. Ifthe immunizing tumor still tested positive, at least
two idiotopes were assigned to it: one shared and one not
shared with the lymphoma used in the absorption. The results
of these analyses are summarized in Table 2.
A minimum of 16 idiotopes is expressed by 23 of the 27
CH lymphomas. Only 4 idiotopes (b, n, o, and p) appear to
be private (i.e., expressed by only 1 tumor); the rest are
shared. At least 7 (a, d, e, f, i, j, and k) of the 12 shared
idiotopes are located on the VH region, as evidenced by their
expression on lymphomas bearing either K or X light chains
(presently available data are uninformative regarding the
involvement of VH or light chain V regions in the expression
of the other 9 idiotopes). Interestingly, each of the tumors
that link four of the five IdX groups bears at least 1 of these
idiotopes. Four of these idiotopes (e, f, i, and k) are also
expressed by the BALB/c myeloma protein, TEPC183.
Antigen Specifcities of CH Lymphomas. Fourteen of the 27
CH lymphomas bind determinants on the surfaces of certain
erythrocytes or E. coli or both (Table 3). We first discovered
that CH12 formed rosettes with SRBC and ChRBC (5).
Subsequently we found that CH12, as well as CH9, CH15,
CH12
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FIG. 2. Specificity of anti-Id sera. The indicated cells were stained with anti-CH12 Id, anti-CH27, or normal rabbit sera and fluorescein
isothiocyanate-conjugated goat anti-rabbit Ig serum and then analyzed by flow cytometry. The minor peak on the CH27 histogram (indicated
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Table 2. Idiotopes expressed by the CH lymphomas
Idiotopes*
Tumor a b c d e f g h i j k I m n o p
CH1 + + - +.
CH9 + - +
CH15 + - + +
CH26 + - NDND-
CH39 + - - + + + -
CH34 + - -
CH2 - - - + -
CH5 - - - +
CH27 - - + - ++.
CH28 - - - + +
CH35 - - - + +
CH32 - - - + + +
CH25 - - - + + - + - - -
CH23 - - - + +
CH12 - - - + + + + - - - -
T183 - ND - - + + - - + - + + - - - -
CH38 - - - + ND ND ND - - - -
CH10 - - - + + - -
CH29 - - +
CH31 - - +
CH33 - - - +
CH36 - - -
CH6 - - - --+ -
CH7 - - +
CH4 - - - ND ND - - - -
CH19 - - -
CH21 - - -
CH30 - - -
ND, not done.
*These idiotopes were defined by 10 xenogeneic anti-Id sera. If an anti-Id
serum reacted with more than one tumor, then it was absorbed with each
tumor and retested on all ofthe lymphomas with which it had reacted. Tumors
that did not now react with the absorbed serum were assigned one idiotope
(shared by the lymphoma used in the absorption). Two idiotopes were
assigned to immunizing tumors which still tested positive with the absorbed
anti-Id serum (one was unique to the immunizing tumor, with respect to the
one used in the absorption, and the other was shared by the two tumors).
CH23, CH27, CH28, CH32, CH34, and CH35, formed
rosettes with syngeneic erythrocytes that had been treated
with bromelain (BrMRBC) (the tumors did not bind untreated
mouse erythrocytes). CH27, CH28, CH32, CH34, and CH35
also formed rosettes with ChRBC and SRBC, although the
percentage of CH34 cells that bound these erythrocytes was
low (15% and 14%, respectively).
CH34 formed rosettes not only with erythrocytes but also
with fluoresceinated E. coli (since CH34 did not bind the
fluoresceinated second step used in the indirect im-
munofluorescence assay, we ruled out fluorescein as the
specific hapten). CH23 also bound E. coli as well as
BrMRBC, but to a lesser extent (13% rosette-forming cells in
both tests). CH1, CH10, CH25, CH31, and CH38 all dis-
played high percentages (>50%) of rosette-forming cells
with E. coli.
For every tumor tested, the binding of erythrocytes or E.
coli was attributable to the surface 1g. Pretreatment of CH10,
CH12, CH27, CH32, CH34, and CH35 with anti-Ig reagents
under capping conditions drastically reduced the numbers of
rosette-forming cells (Table 4). Furthermore, supernatants
from the CH9, CH12, CH15, CH27, and CH28 hybridomas
agglutinated the appropriate erythrocytes (unpublished da-
ta).
DISCUSSION
The CH lymphomas display a restricted repertoire of idi-
otopes and antigen binding specificities. Fourteen of the 27
lymphomas we examined bore surface Ig specific for epitopes
on certain erythrocytes or E. coli or both (Table 3). Twenty-
one CH lymphomas bore at least 1 of 12 shared idiotopes as
defined by seven xenogeneic anti-Id sera (Table 2). Of these
12 idiotopes, at least 7 were located in the VH domain, as
evidenced by their presence on lymphomas bearing either K
Table 3. Antigen specificities of CH lymphomas













































Erythrocyte rosette formation between the CH lymphomas and the
various RBC was determined by mixing the CH lymphoma cells with
RBC at a ratio of 1:250. The mixture was gently centrifuged and
incubated at 4°C for 45 min. The E. coli rosette assay was performed
by mixing the CH lymphoma cells with E. coli at a ratio of 1:100.
The mixture was gently centrifuged, incubated at 4°C for 45 min, and
washed twice in HBSS. -, <5% rosette-forming cells; +, 10-15%
rosette-forming cell; + +, 40-60% rosette-forming cells; +++,
>80%1o rosette-forming cells; ND, not done.
or A light chains (the data were uninformative regarding the
locations of the other idiotopes). Based on these observa-
tions, we hypothesize that the CH lymphomas derive from a
subset of B cells, defined by the expression of a limited
number of VH gene products.
Additional evidence suggests that the CH lymphomas
represent a subset of B cells. Included among the nine CH
lymphomas that bear surface Ig specific for a determinant(s)
on BrMRBC, is a subset of tumors that also bind SRBC and
ChRBC (the ChRBC determinants are not Forssman, major
histocompatibility complex, or major blood group antigens;
unpublished data). To our knowledge, no murine Ig with this
specificity has been reported previously. Therefore, these
tumors do not represent a population of B cells with typical
anti-SRBC or anti-ChRBC specificies.
It is interesting to note that among the nine BrMRBC-bind-
ing lymphomas, all but one (CH9) bear detectable amounts of
Ly-1. Ly-1 is a differentiation antigen present on all T cells
(14) and on 1-2% and 5-10% of splenic B cells in normal and
youngNZB mice, respectively (12). Furthermore, Hayakawa
et al. (15) have shown that all of the B cells that secreted
anti-BrMRBC antibodies (in both NZB and normal mice)
were Ly-l+. They proposed that Ly-1+ B cells are respon-
sible for most of the IgM autoantibodies found in autoimmune
and normal mice. Since at least two-thirds of the CH
lymphomas are Ly-1, they may be derived from this
subpopulation. Indeed, there does appear to be a correlation
between the expression of Ly-1 and at least two CH-associ-
ated IdX (CH12 and CH27 IdX) on normal 2a4b B cells. All
2a4b B cells that can be induced to secrete anti-BrMRBC
3802 Immunology: Pennell et al.
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Table 4. Capping of surface Ig inhibits rosette formation
% of rosette-forming cells with various capping reagents
Tumor Antigen None NRS a-IgM a-IgG a-CH1.2 a-CH6 a-CH9 a-CH10 a-CH12 a-CH27
CH10 E. coli 82 76 2.5 71 2.3 74
CH12 SRBC 96 3 89 95 <1
ChRBC 91 ND ND 93 <1
CH27 SRBC 74 77 <1 73
CH32 SRBC 85 3 73
ChRBC 82 <1 68
BrMRBC 86 11 84
CH34 SRBC 15 3 3
ChRBC 14 <1 <1
BrMRBC 83 20 92
CH35 SRBC 90 85 <1 83 84 29*
ChRBC 92 49 4 ND ND ND
BrMRBC 92 92 37 ND ND ND
Tumor cells were incubated with anti(a)-Id antisera in RPMI 1640 medium for 60 min at 370C before the addition of erythrocytes or E. coli.
The remainder of the assay was performed as described in the text. NRS, normal rat serum; a, anti; ND, not done.
*This value is reduced to <1 when a-CH27 Id was incubated with CH35 cells under noncapping conditions (4°C in Hanks' balanced salt solution
with 0.1% sodium azide).
antibodies by treatment with lipopolysaccharide bear Ly-1.
Pretreatment of these cells with anti-CH12 and anti-CH27 Id
sera plus complement reduces the number of BrMRBC-
specific plaques by approximately half (16).
At least two mechanisms may be involved in the etiology
ofCH lymphomas: one involves antigen recognition, and the
other, Id recognition. It is reasonable to assume that antigen-
driven selection is involved in the etiology of the 6 SRBC-
binding lymphomas, since SRBC comprised at least a part of
the immunizing antigen used to induce each of them. How-
ever, antigen drive cannot be the sole factor contributing to
B-cell lymphomagenesis in 2a4b mice, as the remaining 21
tumors do not bind SRBC, even though all but 1 (CH19) arose
following intense adoptive immunization from SRBC. To
account for these tumors, we propose that a second mecha-
nism involving the recognition (or lack thereof) ofa IdX, may
also be involved in the development of these B-cell
lymphomas. The normal B-cell counterparts in the CH
lymphomas may all express a common VH-encoded "regula-
tory" idiotope, as described by Bona et al. (17) and, as such,
may all be members of a miniregulatory network. Perturba-
tion of this putative network by hyperimmunization with
SRBC, an antigen for which some of the members are
specific, in some way increases the risk of the members for
neoplasia. The peculiar propensity for 2a4b mice to develop
B-cell lymphomas under these conditions, might reflect the
absence of an effective idiotype suppressor system, specific
for the IdX of this network. These findings may have
relevance to the use of anti-Id antibodies for diagnosis or
treatment of B-cell lymphomas. Since the CH lymphomas,
and possibly others, represent an idiotypically restricted
subset of B cells, it should be possible to treat the majority
of these tumors with a mixture of a few anti-Id reagents. The
presence of several CH-associated idiotopes on the TEPC183
Ig (a BALB/c myeloma protein) suggests that the putative
Id-related mechanism involved in the etiology of this series
may not be unique to 2a4b mice. If this is so, then oligo-
specific anti-Id therapy may be possible for a number of
B-cell malignancies.
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